10 terminated. 10 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Terminated 10 |
| Phase 2 | 2 | Terminated 2 |
Follow Hematologic Malignancies: new trials by email Literature Review of Hematologic Malignancies trials Research Report on Hematologic Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors AZD0466 - Advanced Solid Tumors, Lymphoma | Phase 1 | Terminated | AstraZeneca | 9 | 2019-12-16 | 2023-08-02 |
| GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease Itacitinib, Calcineurin inhibitor - Hematologic Malignancies | Phase 1 | Terminated | Incyte Corporation | 84 | 2018-02-27 | 2025-10-21 |
| Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies Nivolumab - Hematologic Malignancies | Phase 1 | Terminated | University of Chicago | 3 | 2017-03-20 | 2020-06-25 |
| A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab - Hematologic Malignancies, Solid Tumor | Phase 1 | Terminated | Pfizer | 249 | 2016-01-28 | 2024-05-10 |
| A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies Biological: ProHema-CB - Hematologic Malignancies | Phase 1 | Terminated | Fate Therapeutics | 3 | 2014-12-01 | 2018-10-10 |
| A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies IPI-145 (duvelisib) - Hematologic Malignancies | Phase 1 | Terminated | SecuraBio | 210 | 2011-10-01 | 2021-03-17 |
| Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps Fludarabine, Thiotepa, Total Body Irradiation (TBI) - Hematologic Malignancies, Acute Leukemia | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 8 | 2011-04-01 | 2025-05-31 |
| Dose Escalation of IPI-493 in Hematologic Malignancies IPI-493 - Hematologic Malignancies | Phase 1 | Terminated | Infinity Pharmaceuticals, Inc. | 4 | 2010-06-01 | 2015-04-15 |
| Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies CAMPATH (alemtuzumab) - Hematologic Malignancies | Phase 1 | Terminated | Genzyme, a Sanofi Company | 24 | 2003-12-01 | 2014-02-05 |
| Stem Cell Transplant for Hematologic Diseases Campath 1H, Fludarabine, Stem Cell Transplant - Hematologic Malignancies | Phase 1 / Phase 2 | Terminated | Baylor College of Medicine | 27 | 2000-08-01 | 2016-11-07 |
Hematologic Neoplasms (10) · Hodgkin Disease (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Anemia, Refractory, with Excess of Blasts (1) · Graft vs Host Disease (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1)
Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Neoplasms (10) · Neoplasms by Site (10) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms by Histologic Type (4) · Bone Marrow Diseases (3) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2)
Alemtuzumab (2) · Nivolumab (2) · Whole-Body Irradiation (2) · fludarabine (2) · AZD0466 (1) · Calcineurin Inhibitors (1) · Cyclosporine (1) · HSP90 Heat-Shock Proteins (1) · Hematopoietic Stem Cell Transplantation (1) · INCB039110 (1) · Melphalan (1) · Radiotherapy (1) · Rituximab (1) · Stem Cell Transplantation (1) · TTI-621 (1)
AstraZeneca (1) · Baylor College of Medicine (1) · Fate Therapeutics (1) · Genzyme, a Sanofi Company (1) · Incyte Corporation (1) · Infinity Pharmaceuticals, Inc. (1) · Pfizer (1) · SecuraBio (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Chicago (1)
United States (10) · Canada (1) · France (1) · Italy (1) · Spain (1)
Chris Storgard, MD (1) · Dolores Grosso, DNP, CRNP (1) · George Carrum, MD (1) · Hagop Youssoufian, MD (1) · Hongtao Liu, MD (1) · Neal Flomenberg, MD (1) · Robert Ross, M.D. (1) · Rodica Morariu-Zamfir, MD (1)
PMID 28017967, PMID 29191916, PMID 29233821, PMID 30962222, PMID 33451977, PMID 36841672
2017 (1)